bluuebunny/crossref_metadata_2025_split huggingface dataset:
Abstract 1854: Oridonin inhibits cell growth of esophageal carcinoma cells via induction of apoptosis
Authors: Zhang Xiaojun , Xing Mengtao , Ma Yangcheng , Wang Xiao , Zhang Jianying 
Published: September 2020

Abstract
Esophageal Cancer estimated leading deaths are more than 400,000 every year in worldwide, while 80% due to esophageal squamous cell carcinoma. In worldwide, esophageal cancer leading death ranks in sixth among cancer leading causes of death, while the 5-year survival rate of esophageal cancer is 19%. Oridonin, a tetracyclic diterpenes compound, has been indicated the anti-tumor activity for digestive system tumors. To assess the anticancer activity of oridonin on esophageal cancer, we performed cell proliferation experiment of oridonin on esophageal squamous cell carcinoma cell line TE-8 using SRB assay. We found that IC50 of oridonin on TE-8 treated for 72h is 3.0μM, which is better than positive control Gemcitabine treatment on TE-8 for 72h (5.7 μM), as well as TE-8 cells shrunk and floated with increasing concentration on oridonin. At the same time, oridonin induced a dose-dependent inhibition of cell colony formation of esophageal cancer cell line. Colony numbers of TE-8 cell line treated with 1μM and 2μM oridonin are 111 and 54, respectively, which are significantly different (p&lt;0.05). Accompanying with marked morphological changes, flow cytometer results showed that oridonin triggered sub-G0/G1 cell cycle arrest in a dose-dependent manner. After treatment by 10μM and 20μM oridonin for 24h, percentage of sub-G0/G1 cells were 25.5 and 55.3%, respectively, which are significantly different (p&lt;0.05). The apoptosis results showed that oridonin treatment led to the accumulation of cells in early-(Annexin V+/PI-) and late-stage (Annexin V+/PI+) apoptosis in a dose-dependent manner.
Citation Format: Xiaojun Zhang, Mengtao Xing, Yangcheng Ma, Xiao Wang, Jianying Zhang. Oridonin inhibits cell growth of esophageal carcinoma cells via induction of apoptosis [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 1854.
Abstract 1864: Generation of a triple-mutation (T790M/C797S/L858R) NSCLC cell line for relevant drug discovery and development
Authors: Ma Huiying , Li Peixue , Zhang Peiran , Sun Fuyun , Lin Qing 
Published: September 2020

Abstract
Epidermal Growth Factor Receptor (EGFR) overexpression is observed in a large subset of patients with non-small-cell lung cancer (NSCLC) and correlated with poor prognosis. Current approved treatment for EGFR mutation-positive NSCLC has been revolutionized with three generations of EGFR tyrosine kinase inhibitors (TKIs): the first- and second-generation TKIs, such as gefitinib, erlotinib and afatinib, selectively targeting EGFR activating mutations existing in exon 19 and 21; and the third-generation EGFR-wild-type sparing, irreversible activating mutations/T790M inhibitor, osimertinib. Patients with somatic activating mutations in the EGFR gene have dramatic response initially, but would eventually develop resistance to these TKIs. One leading evidence of osimertinib resistance is mediated by occurrence of the point mutation C797S. There are no effective therapeutic strategies to overcome this triple-mutation (activating mutations/T790M/C797S) mediated resistance. Therefore, it is urged to develop new drug to target this particular mutant. There is still lack of triple-mutation in vitro model for the new generation drug discovery. In this study, a triple-mutation NSCLC model was generated in the NCI-H1975 lung cancer cell line, which harbors other naturally occurring EGFR genomic aberrations - double-mutation (T790M/L858R) - inherent in NSCLC. We utilized the CRISPR/Cas9 genome editing tool to target endogenous loci in human NSCLC cell line NCI-H1975 and created the intend point mutation, resulting in the triple mutation cell line (T790M/C797S/L858R). Further phenotypic analysis demonstrated that the triple-mutation cell line was resistant to the third generation inhibitors in contrast to the parental double-mutation cell line. This newly developed triple-mutation lung cancer cell line provided a very useful tool for oncology drug discovery for NSCLC.
Citation Format: Huiying Ma, Peixue Li, Peiran Zhang, Fuyun Sun, Qing Lin. Generation of a triple-mutation (T790M/C797S/L858R) NSCLC cell line for relevant drug discovery and development [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 1864.
Abstract 1873: Drivers of secondary resistance to anti-EGFR therapy in metastatic colorectal cancer
Authors: Noseir Soha Hussein , Hahn Stephan , Maghnouj Abdelouahid , Ladigan Swetlana 
Published: September 2020

Abstract
Secondary Resistance (SR) evolves in virtually all metastatic colorectal cancers (mCRC) treated with anti-EGFR targeting drugs such as Cetuximab (Cmab). Yet, SR patient-derived xenograft (pdx) models are largely lacking. Here, we established eight SR pdx models through chronic Cmab treatment of drug-sensitive mCRC pdx. All pdx models were initially wild-type for KRAS, NRAS, PI3K and BRAF, as required for Cmab treatment. Post SR establishment, two models showed KRAS mutations and were excluded from further studies. Whole exome sequencing of the remaining six SR pdx models did not reveal any known driver mutations which could confer SR. However, global gene expression analyses identified widespread transcriptional reprograming with many genes able to activate KRAS and/or PI3K signaling pathways. Among the highly dysregulated genes, fibroblast growth factors FGF13, FGF19, FGF20, and insulin-like growth factor IGF2 stood out as potential drivers of SR through upregulation of RTK signaling.
Functional molecular analyses of these factors were performed using lentiviral vector mediating gene transduction. Cell viability, proliferation assays and western blot (WB) analyses were applied to assess the molecular functionality of FGFs and IGF2-ligands in vitro. Finally, transgenic cell lines were injected into nude mice to test their therapeutic response towards Cmab treatment following upregulation or downregulation of the chosen candidates.
Stable lentiviral overexpression of FGF13 and IGF2 in drug-sensitive cell lines and pdx models triggered SR both in vitro and in vivo. WB analyses showed that FGF13 and IGF2 overexpression induced phosphorylation of pAKT, pS6, and pERK. Conversely, knockdown of IGF2 in a cell line with high endogenous IGF2 expression improved Cmab sensitivity. Lastly, when subjecting a Cmab SR pdx model with high endogenous overexpression of FGF13 and FGF19 to a Pan-FGF inhibitor (LY2874455) in combination with Cmab, we observed a conversion of the SR into partial response.
Taken together, these results support a role of IGF2 and FGFs as candidate proteins conferring SR in an autocrine fashion in the setting of KRAS wild-type mCRC under chronic anti-EGFR treatment. Importantly, these results also suggest that potential combination therapies of Cmab and an IGF2 or FGF inhibitor could prevent establishment of SR through these pathways and offer new treatment opportunities for patients with SR mCRC.
Citation Format: Soha Hussein Noseir, Stephan Hahn, Abdelouahid Maghnouj, Swetlana Ladigan. Drivers of secondary resistance to anti-EGFR therapy in metastatic colorectal cancer [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 1873.
Abstract 1887: Tumor-stroma interactions mediated by Semaphorin 6A as a determinant of drug resistance in BRAF-mut melanoma
Authors: Loria Rossella , Falcone Italia , Martile Marta Di , Caprara Valentina , Fraioli Rocco , Laquintana Valentina , Bon Giulia , Rosanò Laura , Bufalo Donatella Del , Ciuffreda Ludovica , Ferraresi Virginia , Milella Michele , Falcioni Rita 
Published: September 2020

Abstract
In BRAF-mutant (BRAF-mut) melanoma combined BRAF/MEK inhibition increases survival. However, pharmacological effects on the genetically “normal” tumor microenvironment (i.e. paradox MAPK activation) may set the stage for the development of drug resistance.
In melanoma specimens, we observed a significant correlation between BRAF-mut and the expression of Semaphorin 6A (Sema6A), a member of the semaphorin family that regulates actin cytoskeleton remodeling, motility and cell proliferation. In BRAF-mut melanoma cell lines, Sema6A is involved in cytoskeleton remodeling by regulation of YAP activity. Sema6A depletion induced a decrease in RhoA activation and, consequently, an increase in phospho-YAP and a reduction in cell proliferation rate. We thus hypothesized that actin cytoskeleton remodeling and dynamic evolutions may play a role in both cell autonomous and stroma-mediated mechanisms of drug-resistance in this context.
To assess the functional relevance of Sema6A expression in the regulation of melanoma/stroma interactions and sensitivity/resistance to pathway inhibitors, we performed an inducible Sema6A knock down in BRAF-mut melanoma cell lines and evaluated the response to BRAF/MEK inhibitors in monolayer and 2D co-culture systems. In contexts of partial response or resistance in vitro, BRAF inhibitors, alone or combined with MEK inhibitors, were increased Sema6A expression at the mRNA and protein levels in both monolayer and 2D co-culture systems. Furthermore, Sema6A silencing performed in 2D co-culture system abrogated the protective effect of melanoma/stroma interactions, resulting in a synergistic effect with BRAF/MEK inhibitors.
Overall, our results suggest that Sema6A could be a crucial mediator of protective tumor/stroma interactions, involved in resistance to MAPK inhibition in melanoma.
Citation Format: Rossella Loria, Italia Falcone, Marta Di Martile, Valentina Caprara, Rocco Fraioli, Valentina Laquintana, Giulia Bon, Laura Rosanò, Donatella Del Bufalo, Ludovica Ciuffreda, Virginia Ferraresi, Michele Milella, Rita Falcioni. Tumor-stroma interactions mediated by Semaphorin 6A as a determinant of drug resistance in BRAF-mut melanoma [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 1887.
Abstract 1896: Whole transcriptome analysis identifies TNS4 as a key effector of cetuximab and a regulator of the oncogenic activity of KRAS mutant colorectal cancer cell lines
Authors: Kim Sujin , Kim Nayoung , Kang Keunsoo , Kim Wonkyung , Won Jonghwa , Cho Jeonghee 
Published: September 2020

Abstract
Targeting of activated epidermal growth factor receptor (EGFR) with therapeutic anti-EGFR monoclonal antibodies (mAbs) such as cetuximab and panitumumab has been used as an effective strategy in treatment of colorectal cancer (CRC). However, its clinical efficacy occurs only in the limited number of patients. Here, we performed whole-transcriptome analysis in xenograft mouse tumors induced by KRASG12D mutation-bearing LS174T CRC cells following treatment with either cetuximab or PBS. By integrated analyses of differential gene expression with TCGA and CCLE public database, we identified TNS4, overexpressed in CRC patients and KRAS mutation-harboring CRC cell lines, significantly downregulated by cetuximab. While ablation of TNS4 expression via shRNA results in significant growth inhibition of LS174T, DLD1, WiDr, and DiFi CRC cell lines, conversely, its ectopic expression increases the oncogenic growth of these cells. Furthermore, TNS4 expression is transcriptionally regulated by MAP kinase signaling pathway. Consistent with this finding, selumetinib, a MEK1/2 inhibitor, suppressed oncogenic activity of CRC cells and this effect is more profound in combination with cetuximab. Altogether, we propose that TNS4 plays a crucial role in CRC tumorigenesis and that suppression of TNS4 would be an effective therapeutic strategy in treating a subset of cetuximab-refractory CRC patients including KRAS activating mutations.
Citation Format: Sujin Kim, Nayoung Kim, Keunsoo Kang, Wonkyung Kim, Jonghwa Won, Jeonghee Cho. Whole transcriptome analysis identifies TNS4 as a key effector of cetuximab and a regulator of the oncogenic activity of KRAS mutant colorectal cancer cell lines [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 1896.
Abstract 1908: Kinome rewiring upon acquisition of resistance to PI3K inhibitors in ER+ breast cancer
Authors: Griffin Jacqueline Reedy , Traphagen Nicole , Kettenbach Arminja , Miller Todd 
Published: September 2020

Abstract
Hyperactivation of the phosphatidylinositol-3 kinase (PI3K) pathway is a critical step in oncogenesis and plays a role in the development of treatment resistance in estrogen receptor-positive (ER+) breast cancer. Targeted inhibition of PI3K (PI3Ki) was recently approved in combination with endocrine therapy for advanced ER+ breast cancer. As most tumor-targeted therapies are encumbered by the development of secondary resistance, there remains a need to identify novel therapeutic strategies to prevent and overcome PI3Ki resistance. We treated mice bearing anti-estrogen-resistant ER+ breast cancer xenografts with the anti-estrogen fulvestrant +/- the pan-PI3Ki GDC-0941. The drug combination induced partial regression of tumors, followed by regrowth despite continued drug treatment. We harvested tumors before, during, and after acquisition of resistance to the drug combination and performed quantitative phosphoproteomic profiling. Using LC-MS/MS, we identified 203 phosphopeptides and 227 unique phosphorylation sites in the drug-resistant tumors, with clusters of 87 upregulated and 116 downregulated phosphopeptides. The NetPhorest analysis platform predicted hyperactivation of 6 kinases and hypoactivation of 16 kinases in drug-resistant tumors. Notably, two hyperactive kinases, MAPK1 and HIPK2, were predicted to target substrates MARKS (at Ser27 in the calcium binding domain) and NS1BP (at Ser322 in the homeodomain kelch repeat). MARCKS is a filamentous actin cross-linking protein, while the kelch repeats of NS1BP are known to associate with F-actin to stabilize actin filaments. In addition, the most significant predicted kinase among the cluster of 116 downregulated phosphopetides in the drug-resistant tumors was “PKCiota”, predicted to target PARD3 at Ser852. Previous work showed that PARD3 is central for the formation of tight junctions. These data collectively suggest a dynamic role of kinase-substrate interactions involved in resistance to combined anti-estrogen/PI3Ki treatment, including filamentation actin formation and stabilization, as well as the deregulation of tight junction formation.
Citation Format: Jacqueline Reedy Griffin, Nicole Traphagen, Arminja Kettenbach, Todd Miller. Kinome rewiring upon acquisition of resistance to PI3K inhibitors in ER+ breast cancer [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 1908.
Abstract 1922: Tamoxifen detection by molecular fluorescence in breast cancer patients as a screening for metabolizer classification
Authors: Costa Lorenna Larissa Ferreira , de Freitas Daniel Lucas Dantas , de Lima Kassio Michell Gomes , Lajus Tirzah Braz Petta 
Published: September 2020

Abstract
Breast cancer patients with polymorphic changes in the CYP2D6 gene show considerable variations in tamoxifen (TMX) bioavailability due to the need for bioactivation of this drug. Therefore, patients with such allelic changes have a worse prognosis compared to controls. Biospectroscopy allows the analysis of biofluids, providing the complete characterization of all molecules present in the biological matrix. Among spectroscopic techniques, molecular fluorescence stands out for its high analytical sensitivity in the broad identification of information obtained by the excitation-emission fluorescence matrix (EEM). This allows the specific measurement of fluorescent species in the sample. Quantification of TMX by fluorescence spectroscopy provides a phenotypic assessment of the patient's pharmacological metabolizing status, leading to a personalized and effective pharmacological therapy. We applied fluorescence spectroscopy to blood samples from n=20 women, who had genotyping of the CYP2D6*4_g.1846G&gt;A allele, which confers decreased protein activity. We were able to demonstrate that the fluorescence signal generated by the TMX structure in plasma solution could be detected using our methodology. The data collected exhibited signal interference due to the numerous molecular species present in this matrix. However, using multivariate statistical algorithms we could extract relevant information from the analyte, improving the signal / noise of the emission-excitation matrix. Finally, we were able to demonstrate that low cost method, which can be performed rapidly, may allow for a simple point of care stratification of patients by the CYP2D6 status, which in turn may allow for increased personalization of tamoxifen therapy for breast cancer patients.
Citation Format: Lorenna Larissa Ferreira Costa, Daniel Lucas Dantas de Freitas, Kassio Michell Gomes de Lima, Tirzah Braz Petta Lajus. Tamoxifen detection by molecular fluorescence in breast cancer patients as a screening for metabolizer classification [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 1922.
Abstract 1928: Study of copy number amplification and chemo-response in triple negative breast cancer
Authors: Grainger Jordan Mark , Yu Jia , Kalari Krishna R. , Vedell Peter , Thompson Kevin , Goetz Matthew P. , Suman Vera J. , Boughey Judy C. , Wang Liewei 
Published: September 2020

Abstract
Triple negative breast cancer (TNBC) accounts for 15-20% of breast cancer cases in the United States. With currently no targeted therapies for TNBC, identification of novel biomarkers to improve chemo-response is vital. Recently, copy number amplifications (CNAs) have been implicated in treatment response in several diseases including breast cancer. Our clinical studies have associated a 5 Mb CNA in TNBC patients with chemo-response, which may elucidate novel biomarkers and treatment strategies for TNBC. Analysis of RNAseq and Whole Exome Sequencing data from 42 TNBC patient tumors enrolled in the BEAUTY Study, identified a 5 Mb CNA on chromosome 8q which associated with pathological complete response following taxane and anthracycline chemotherapy. By performing siRNA knockdown cytotoxicity studies in TNBC cell lines for genes within this amplified region, we identified RDH10 as a potential novel biomarker for increasing chemo-sensitivity. RDH10 is the rate limiting step in the synthesis of all-trans retinoic acid (ATRA). Previous studies have demonstrated ATRA to be a potent inhibitor of PIN1, a key regulator of several oncogenic signaling pathways, amplified in TNBC. We discovered overexpression of RDH10 to increase endogenous levels of ATRA, contributing to the degradation of PIN1 and taxane sensitivity. A rescue experiment with PIN1 was able to restore the chemo-resistance phenotype. Similarly, we found treating TNBC cells with ATRA phenocopied RDH10's effect on PIN1 and improved chemo-sensitivity. Furthermore, analyses of chemo-responsive PDX tumors containing the 5 Mb CNA, overexpressed RDH10 and exhibited lower levels of PIN1 when compared to non-responders. In conclusion, RDH10 amplification increases endogenous levels of ATRA and degrades PIN1 in TNBC. ATRA-mediated degradation of PIN1 sensitizes TNBC to chemotherapy, suggesting RDH10 as a novel biomarker for chemo-response and ATRA as a novel treatment to improve chemo-sensitivity.
Citation Format: Jordan Mark Grainger, Jia Yu, Krishna R. Kalari, Peter Vedell, Kevin Thompson, Matthew P. Goetz, Vera J. Suman, Judy C. Boughey, Liewei Wang. Study of copy number amplification and chemo-response in triple negative breast cancer [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 1928.
Abstract 1937: BPR6K609: An Aurora kinase inhibitor targeting small cell lung cancer with MYC amplification
Authors: Chi Ya-Hui , Chang Chun-Ping , Ke Yi-Yu , Lin Wen-Hsing , Wang Wan-Ping , Tsai Chia-Hua , Chen Yen-Ting , Su Yu-Jie , Hung Ming-Chun , Wu Zhong-Wei , Wu Mine-Hsine , Yeh Teng-Kuang , Chen Ching-Ping , Song Jen-Shin , Chen Chiung-Tong , Shih Chuan 
Published: September 2020

Abstract
Small cell lung cancer (SCLC) accounts for approximately 15% of all lung cancers, leading to ~30,000 deaths each year in the United States. SCLC patients often present with metastasis at time of diagnosis, excluding surgery as a treatment option. While patients show high response rate to standard chemotherapy such as cisplatin/etoposide, they soon develop drug resistance and disease progression. Therefore, new therapeutic strategies are urgently needed for SCLC. BPR6K609S0 is a novel Aurora kinase inhibitor which has been designed to inhibit the kinase activity of Aurora A, and induces proteasome-mediated degradation of MYC. The BPR6K609S0 active molecule provokes cell apoptosis and inhibits proliferation of several SCLC cell lines with IC50 &lt; 100 nM. Oral administration of BPR6K609 induces &gt;60 % tumor regression in a NCI-H446 xenograft mouse model. In addition, BPR6K609 further reduces tumor progression in NCI-H446 xenograft mice pre-treated with LY3295668, an Aurora A-selective inhibitor which is currently under clinical investigation. These results support the clinical potential of BRP6K609S0 for the treatment of SCLC.
Citation Format: Ya-Hui Chi, Chun-Ping Chang, Yi-Yu Ke, Wen-Hsing Lin, Wan-Ping Wang, Chia-Hua Tsai, Yen-Ting Chen, Yu-Jie Su, Ming-Chun Hung, Zhong-Wei Wu, Mine-Hsine Wu, Teng-Kuang Yeh, Ching-Ping Chen, Jen-Shin Song, Chiung-Tong Chen, Chuan Shih. BPR6K609: An Aurora kinase inhibitor targeting small cell lung cancer with MYC amplification [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 1937.